Astera Labs Inc (NASDAQ: ALAB) Loses -40.80% From High. Why That Could Change?

Currently, there are 164.91M common shares owned by the public and among those 125.56M shares have been available to trade.

The company’s stock has a 5-day price change of -8.44% and 18.27% over the past three months. ALAB shares are trading 38.16% year to date (YTD), with the 12-month market performance down to -34.12% lower. It has a 12-month low price of $36.22 and touched a high of $147.39 over the same period. ALAB has an average intraday trading volume of 4.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.30%, 7.39%, and 3.15% respectively.

Institutional ownership of Astera Labs Inc (NASDAQ: ALAB) shares accounts for 60.35% of the company’s 164.91M shares outstanding.

It has a market capitalization of $14.39B and a beta (3y monthly) value of 1.34. The stock’s trailing 12-month PE ratio is 371.95, while the earnings-per-share (ttm) stands at $0.23. The company has a PEG of 8.92 and a Quick Ratio of 13.26 with the debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.03% over the week and 4.12% over the month.

Analysts forecast that Astera Labs Inc (ALAB) will achieve an EPS of 0.32 for the current quarter, 0.34 for the next quarter and 1.72 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.32 while analysts give the company a high EPS estimate of 0.32. Comparatively, EPS for the current quarter was 0.13 a year ago. Earnings per share for the fiscal year are expected to increase by 60.69%, and 27.78% over the next financial year.

Susquehanna coverage for the Astera Labs Inc (ALAB) stock in a research note released on May 16, 2025 offered a Neutral rating with a price target of $80. Morgan Stanley was of a view on May 12, 2025 that the stock is Overweight, while Raymond James gave the stock Outperform rating on March 14, 2025, issuing a price target of $82. Northland Capital on their part issued Outperform rating on January 28, 2025.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.